All News
Could Methotrexate Work in Hand Osteoarthritis?
Lancet reports the results of the METHODS study from Australia where hand osteoarthritis (HOA) patients benefitted from 6 months of methotrexate (MTX) - as long as there was MRI synovitis!
Read Article
IL-6 Inhibitors in #PMR: Give early or late?
https://t.co/Hg7ZJJxaGD https://t.co/cJdnTPI3YD
Dr. John Cush RheumNow ( View Tweet)
AbbVie US Medical Affairs sponsored posters are now available:
Long-term Safety of a JAKi in Patients with RA With up to 6.5 Years of Exposure. https://t.co/0PQT6qExcQ https://t.co/PYbdwQeKEA
Dr. John Cush RheumNow ( View Tweet)
Steroids and #PMR
In this Tuesday Night Rheumatology webinar, the panel discussed the use of corticosteroids in patients with polymyalgia rheumatica. Panelists: Drs. Lindsay Lally, Richard Conway and Max Yates. Moderated by Dr. David Liew.
https://t.co/t27SldsJ9z https://t.co/8knPPLw3OE
Dr. John Cush RheumNow ( View Tweet)
Rheumatologist Survey on PMR & steroid-sparing. What percentage of PMR pts do you use a steroid-sparing agent? Answer here: https://t.co/rIMzlyYZst
Links:
Dr. John Cush RheumNow ( View Tweet)
53.2 Million with Diagnosed Arthritis (USA: 2019–2021)
Last week the CDC's MMWR reports that during 2019–2021, 21.2% of U.S. adults (53.2 million) reported "diagnosed arthritis"
https://t.co/UKtR0q40cU https://t.co/9Wb1dAtzDJ
Dr. John Cush RheumNow ( View Tweet)
Curious about the latest updates in treating axSpA? Don't miss out on the RheumNow Therapeutic Update! This engaging video series explores the current recommendations from the ASAS-EULAR Guidelines. https://t.co/Zto7we8z6M https://t.co/TvXzsFUZ46
Dr. John Cush RheumNow ( View Tweet)
Innovative, full-read, state-of-the-art article on IMAGING in INFLAMMATORY ARTHRITIS & its future role in precision medicine. "Imaging is poised to become an invaluable tool in precision medicine..". HR-pQCT, 3T or 7T MRI, FAPI PET–CT, CEUS, FOI, etc https://t.co/JlZZf2KZdi https://t.co/eSpE9RAcvB
Dr. John Cush RheumNow ( View Tweet)
Canadian survey of 620 pts w/ chronic & debilitating arthritis, shows the majority (76%) are free of psychiatric disorders (76%) & in good (complete) mental health (56%); fostered by having a confidant, & being without insomnia, depression/anxiety https://t.co/6agOYCmnit https://t.co/IBKCjUo0DQ
Dr. John Cush RheumNow ( View Tweet)
Turkish study 1,134 PsA pts found mean Dx delay=35 mos (median: 12). 39% Dx w/in 3 mos, & 67% w/in 24 mos. Dx delay decr. over time: 60 to 24 mos (<2010 to 2015–2019). Dx delay factors: less education (OR 2.6), arthritis>PSO (1.7), LBP 1st (1.6)https://t.co/GYKPSaYWhU https://t.co/YYwaiQd5mJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Tomorrow! Join us for #PMR & Steroid-Sparing Therapeutics featuring panelists Drs. Robert Spiera and Sarah Mackie, and moderator Dr. Sebastian Sattui .
https://t.co/UjtWAvSOXU https://t.co/LbZKybkAzK
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves IV Secukinumab
On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)
https://t.co/zv7b98ZUjS https://t.co/1rXjYIbLpw
Dr. John Cush RheumNow ( View Tweet)
Full Read review of #PMR in Lancet:
- Start @ 12·5–25mg prednisone qd
- Remission in most but, relapses in 40–60%
- Onset sudden; AM stiffness predominates; Shoulders>Pelvic
~50% have distal MSK Sxs
- US: look for B/L sub-acromial/deltoid bursitis https://t.co/0j1nRmdizP https://t.co/7cURm1pQeB
Links:
Dr. John Cush RheumNow ( View Tweet)
#PMR: glad or bad tidings?
Please don’t tell your patient that PMR “typically” lasts two years. Because it probably won’t last exactly two years, and then they’ll be less inclined to believe other things you say.
Read more...
https://t.co/UXuUzEVjFI
@sarah_L_mackie https://t.co/UnXsyuq4V4
Dr. John Cush RheumNow ( View Tweet)
Hepatotoxicity related to Anakinra has been reported in pediatric rheumatology patients. LFT elevations have been reported with IL-1 inhibition, even after excluding LFTs from the inflamm Dx, other drugs, MAS, etc. Here are 3 case reports. https://t.co/6ZxIcHbUEd https://t.co/Cx0kbn7JU2
Dr. John Cush RheumNow ( View Tweet)
FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/XiikNr3hWO https://t.co/Xd66zgvoDv
Dr. John Cush RheumNow ( View Tweet)
Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure
Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/c4mYjdLKW7 https://t.co/lXh5klx0cq
Dr. John Cush RheumNow ( View Tweet)
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
https://t.co/k5SAshxdsg https://t.co/tMtRHn2C6j
Dr. John Cush RheumNow ( View Tweet)
Registration is now open! Early bird pricing is available until 11/30/23. See you there!
https://t.co/zjXyldwlyl https://t.co/CpQ00745c1
Links:
Dr. John Cush RheumNow ( View Tweet)
#PMR: Is There Hidden GCA?
Dr. Anisha Dua, asks the question: in PMR should you worry about occult GCA?
https://t.co/Cd6u2GwJuo
@anisha_dua https://t.co/dWUH4zudPc
Links:
Dr. John Cush RheumNow ( View Tweet)